Best Practice & Research Clinical Rheumatology
Volume 21, Issue 5 , Pages 943-967 , October 2007

The course of established rheumatoid arthritis

  • David L. Scott (Professor of Clinical Rheumatology)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 207 848 5215; Fax: +44 207 848 5202.

References 

  1. Scott DL, Huskisson EC. The course of rheumatoid arthritis. Baillieres Clinical Rheumatology. 1992;6:1–21
  2. Short CL, Bauer W. The course of rheumatoid arthritis in patients receiving simple medical and surgical measures. New England Journal of Medicine. 1948;238:142–148
  3. Short CL, Bauer W, Reynolds WE. Rheumatoid Arthritis. Cambridge, Massachusetts: Harvard University Press; 1957;
  4. Short CL. Rheumatoid arthritis: types of course and prognosis. Medical Clinics of North America. 1968;52:549–557
  5. Bevans M, Nadell J, Demartini F, Ragan C. The systemic lesions of malignant rheumatoid arthritis. The American Journal of Medicine. 1954;16:197–211
  6. Masi AT. Articular patterns in the early course of rheumatoid arthritis. The American Journal of Medicine. 1983;75:16–26
  7. Symmons DP, Silman AJ. Aspects of early arthritis. What determines the evolution of early undifferentiated arthritis and rheumatoid arthritis? An update from the Norfolk Arthritis Register. Arthritis Research & Therapy. 2006;8:214
  8. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism. 1988;31:315–324
  9. Bunn DK, Shepstone L, Galpin LM, et al. The NOAR Damaged Joint Count (NOAR-DJC): a clinical measure for assessing articular damage in patients with early inflammatory polyarthritis including rheumatoid arthritis. Rheumatology (Oxford). 2004;43:1519–1525
  10. Lindqvist E, Saxne T, Geborek P, Eberhardt K. Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage. Annals of the Rheumatic Diseases. 2002;61:1055–1059
  11. Grassi W, De Angelis R, Lamanna G, Cervini C. The clinical features of rheumatoid arthritis. European Journal of Radiology. 1998;27(supplement 1):S18–S24
  12. Visser H, le Cessie S, Vos K, et al. How to diagnose rheumatoid arthritis early: a prediction model for persistent erosive) arthritis. Arthritis and Rheumatism. 2002;46:357–365
  13. Guerne P-A, Weisman MH. Palindromic rheumatism: part of or apart from the spectrum of rheumatoid arthritis. The American Journal of Medicine. 1992;93:451–458
  14. Russell AS, Devani A, Maksymowych WP. The role of anti-cyclic citrullinated peptide antibodies in predicting progression of palindromic rheumatism to rheumatoid arthritis. The Journal of Rheumatology. 2006;33:1240–1242
  15. Salvador G, Gomez A, Vinas O, et al. Prevalence and clinical significance of anti-cyclic citrullinated peptide and antikeratin antibodies in palindromic rheumatism. An abortive form of rheumatoid arthritis?. Rheumatology Oxford. 2003;42:972–975
  16. Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. The Journal of Rheumatology. 1996;23:1407–1417
  17. Pollard LC, Choy EH, Gonzalez J, et al. Fatigue in rheumatoid arthritis reflects pain, not disease activity. Rheumatology (Oxford). 2006;45:885–889
  18. Wolfe F, Michaud K. Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize ra patients with fibromyalgia. The Journal of Rheumatology. 2004;31:695–700
  19. Turkcapar N, Demir O, Atli T, et al. Late onset rheumatoid arthritis: clinical and laboratory comparisons with younger onset patients. Archives of Gerontology and Geriatrics. 2006;42:225–231
  20. Pease CT, Haugeberg G, Morgan AW, et al. Diagnosing late onset rheumatoid arthritis, polymyalgia rheumatica, and temporal arteritis in patients presenting with polymyalgic symptoms. A prospective longterm evaluation. The Journal of Rheumatology. 2005;32:1043–1046
  21. Pease CT, Bhakta BB, Devlin J, Emery P. Does the age of onset of rheumatoid arthritis influence phenotype? a prospective study of outcome and prognostic factors. Rheumatology (Oxford). 1999;38:228–234
  22. Bajocchi G, La Corte R, Locaputo A, et al. Elderly onset rheumatoid arthritis: clinical aspects. Clinical and Experimental Rheumatology. 2000;18(4 supplement 20):S49–S50
  23. Yazici Y, Paget SA. Elderly-onset rheumatoid arthritis. Rheumatic Diseases Clinics of North America. 2000;26:517–526
  24. Papadopoulos IA, Katsimbri P, Alamanos Y, et al. Early rheumatoid arthritis patients: relationship of age. Rheumatology International. 2003;23:70–74
  25. Calvo-Alen J, Corrales A, Sanchez-Andrada S, et al. Outcome of late-onset rheumatoid arthritis. Clinical Rheumatology. 2005;24:485–489
  26. Goronzy JJ, Weyand CM. Aging, autoimmunity and arthritis: T-cell senescence and contraction of T-cell repertoire diversity - catalysts of autoimmunity and chronic inflammation. Arthritis Research & Therapy. 2003;5:225–234
  27. Straub RH, Scholmerich J, Cutolo M. The multiple facets of premature aging in rheumatoid arthritis. Arthritis and Rheumatism. 2003;48:2713–2721
  28. Cutolo M, Sulli A, Pizzorni C, et al. Hypothalamic-pituitary-adrenocortical and gonadal functions in rheumatoid arthritis. Annals of the New York Academy of Sciences. 2003;992:107–117
  29. Rall LC, Roubenoff R. Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatology (Oxford). 2004;43:1219–1223
  30. Krishnan E, Hakkinien A, Sokka T, Hannonen P. Impact of age and comorbidities on the criteria for remission and response in rheumatoid arthritis. Annals of the Rheumatic Diseases. 2005;64:1350–1352
  31. McCarty DJ, O'Duffy JD, Pearson L, Hunter JB. Remitting seronegative symmetrical synovitis with pitting edema. RS3PE syndrome. Journal of the American Medical Association. 1985;254:2763–2767
  32. Russell EB, Hunter JB, Pearson L, McCarty DJ. Remitting, seronegative, symmetrical synovitis with pitting edema—13 additional cases. The Journal of Rheumatology. 1990;17:633–639
  33. Chaouat D, Le Parc JM. The syndrome of seronegative symmetrical synovitis with pitting edema (RS3 PE syndrome): a unique form of arthritis in the elderly? Report of 4 additional cases. The Journal of Rheumatology. 1989;16:1211–1213
  34. Klauser A, Frauscher F, Halpern EJ, et al. Remitting seronegative symmetrical synovitis with pitting edema of the hands: ultrasound, color doppler ultrasound, and magnetic resonance imaging findings. Arthritis and Rheumatism. 2005;53:226–233
  35. Russell EB. Remitting seronegative symmetrical synovitis with pitting edema syndrome: followup for neoplasia. The Journal of Rheumatology. 2005;32:1760–1761
  36. Klareskog L, Padyukov L, Ronnelid J, Alfredsson L. Genes, environment and immunity in the development of rheumatoid arthritis. Current Opinion in Immunology. 2006;18:650–655
  37. Huizinga TW, Amos CI, van der Helm-van Mil AH, et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis and Rheumatism. 2005;52:3433–3438
  38. Weyand CM, McCarthy TG, Goronzy JJ. Correlation between disease phenotype and genetic heterogeneity in rheumatoid arthritis. The Journal of Clinical Investigation. 1995;95:2120–2126
  39. Sesin CA, Bingham CO. Remission in rheumatoid arthritis: wishful thinking or clinical reality?. Seminars in Arthritis and Rheumatism. 2005;35:185–196
  40. Mottonen T, Paimela L, Ahonen J, et al. Outcome in patients with early rheumatoid arthritis treated according to the ‘sawtooth’ strategy. Arthritis and Rheumatism. 1996;39:996–1005
  41. Prevoo ML, van Gestel AM, van T Hof MA, et al. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. British Journal of Rheumatology. 1996;35:1101–1105
  42. Sokka T, Hannonen P. Utility of disease modifying antirheumatic drugs in ‘sawtooth’ strategy. A prospective study of early rheumatoid arthritis patients up to 15 years. Annals of the Rheumatic Diseases. 1999;58:618–622
  43. Harrison B, Symmons D. Early inflammatory polyarthritis: results from the Norfolk Arthritis Register with a review of the literature. II. Outcome at three years. Rheumatology (Oxford). 2000;39:939–949
  44. Young A, Dixey J, Cox N, et al. How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS). Rheumatology (Oxford). 2000;39:603–611
  45. Gossec L, Dougados M, Goupille P, et al. Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Annals of the Rheumatic Diseases. 2004;63:675–680
  46. Carmona L, Gonzalez-Alvaro I, Balsa A, et al. Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. Annals of the Rheumatic Diseases. 2003;62:897–900
  47. Schumacher HR, Habre W, Meador R, Hsia EC. Predictive factors in early arthritis: long-term followup. Seminars in Arthritis and Rheumatism. 2004;33:264–272
  48. Tengstrand B, Ahlmen M, Hafstrom I. The influence of sex on rheumatoid arthritis: a prospective study of onset and outcome after 2 years. The Journal of Rheumatology. 2004;31:214–222
  49. Verstappen SM, van Albada-Kuipers GA, Bijlsma JW, et al. Utrecht Rheumatoid Arthritis Cohort Study Group (SRU). A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. Annals of the Rheumatic Diseases. 2005;64:38–43
  50. Mäkinen H, Kautiainen H, Hannonen P, Sokka T. Frequency of remissions in early rheumatoid arthritis defined by 3 sets of criteria. a 5-year followup study. The Journal of Rheumatology. 2005;32:796–800
  51. Stockman A, Tait BD, Wolfe R, et al. Clinical, laboratory and genetic markers associated with erosions and remission in patients with early inflammatory arthritis: a prospective cohort study. Rheumatology International. 2006;26:500–509
  52. Pollard L, Choy EH, Scott DL. The consequences of rheumatoid arthritis: quality of life measures in the individual patient. Clinical and Experimental Rheumatology. 2005;23(5 supplement 39):S43–S52
  53. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. Journal of the American Medical Association. 1949;140:659–662
  54. Scott DL, Pugner K, Kaarela K, et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford). 2000;39:122–132
  55. Ragan C. The clinical features of rheumatoid arthritis. Prognostic indices. Journal of the American Medical Association. 1962;181:663–667
  56. Duthie JJ, Brown PE, Truelove LH, et al. Course and prognosis in rheumatoid arthritis. A further report. Annals of the Rheumatic Diseases. 1964;23:193–204
  57. Jacoby RK, Jayson MI, Cosh JA. Onset, early stages, and prognosis of rheumatoid arthritis: a clinical study of 100 patients with 11-year follow-up. British Medical Journal. 1973;2:96–100
  58. Amor B, Herson D, Cherot A, Delbarre F. Follow-up study of patients with rheumatoid arthritis over a period of more than 10 years (1966-1978): analysis of disease progression and treatment in 100 cases (author's transl). Annales De Médecine Interne. 1981;132:168–173
  59. Rasker JJ, Cosh JA. The natural history of rheumatoid arthritis: a fifteen year follow-up study. The prognostic significance of features noted in the first year. Clinical Rheumatology. 1984;3:11–20
  60. Scott DL, Coulton BL, Chapman JH, et al. The long-term effects of treating rheumatoid arthritis. Journal of the Royal College of Physicians of London. 1983;17:79–85
  61. Scott DL, Symmons DP, Coulton BL, Popert AJ. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet. 1987;1:1108–1111
  62. Pincus T, Callahan LF, Sale WG, et al. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis and Rheumatism. 1984;27:864–872
  63. Sherrer YS, Bloch DA, Mitchell DM, et al. The development of disability in rheumatoid arthritis. Arthritis and Rheumatism. 1986;29:494–500
  64. Isacson J, Allander E, Brostrom LA. A seventeen-year follow-up of a population survey of rheumatoid arthritis. Scandinavian Journal of Rheumatology. 1987;16:145–152
  65. Minaur NJ, Jacoby RK, Cosh JA, et al. Outcome after 40 years with rheumatoid arthritis: a prospective study of function, disease activity, and mortality. The Journal of Rheumatology. 2004;69(supplement):3–8
  66. Watanabe K, Urata S, Suzuki K, et al. Progressive and nonprogressive rheumatoid arthritis over a 10-year period in Japan. The Journal of Rheumatology. 2004;69(supplement):27–29
  67. Gardiner PV, Sykes HR, Hassey GA, Walker DJ. An evaluation of the Health Assessment Questionnaire in long-term longitudinal follow-up of disability in rheumatoid arthritis. British Journal of Rheumatology. 1993;32:724–728
  68. Leymarie F, Jolly D, Sanderman R, et al. Life events and disability in rheumatoid arthritis: a European cohort. British Journal of Rheumatology. 1997;36:1106–1112
  69. Drossaers-Bakker KW, de Buck M, van Zeben D, et al. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis and Rheumatism. 1999;42:1854–1860
  70. Wolfe F. A reappraisal of HAQ disability in rheumatoid arthritis. Arthritis and Rheumatism. 2000;43:2751–2761
  71. Gordon P, West J, Jones H, Gibson T. A 10 year prospective followup of patients with rheumatoid arthritis 1986-96. The Journal of Rheumatology. 2001;28:2409–2415
  72. Welsing PM, van Gestel AM, Swinkels HL, et al. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis and Rheumatism. 2001;44:2009–2017
  73. Wiles NJ, Scott DG, Barrett EM, et al. Benchmarking: the five year outcome of rheumatoid arthritis assessed using a pain score, the Health Assessment Questionnaire, and the Short Form-36 (SF-36) in a community and a clinic based sample. Annals of the Rheumatic Diseases. 2001;60:956–961
  74. Kobelt G, Jonsson L, Lindgren P, et al. Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis and Rheumatism. 2002;46:2310–2319
  75. Deodhar AA, Brabyn J, Pande I, et al. Hand bone densitometry in rheumatoid arthritis, a five year longitudinal study: an outcome measure and a prognostic marker. Annals of the Rheumatic Diseases. 2003;62:767–770
  76. Krishnan E, Tugwell P, Fries JF. Percentile benchmarks in patients with rheumatoid arthritis: Health Assessment Questionnaire as a quality indicator (QI). Arthritis Research & Therapy. 2004;6:R505–R513
  77. Cohen JD, Dougados M, Goupille P, et al. Health assessment questionnaire score is the best predictor of 5-year quality of life in early rheumatoid arthritis. The Journal of Rheumatology. 2006;33:1936–1941
  78. Odegard S, Landewe R, van der Heijde D, et al. Association of early radiographic damage with impaired physical function in rheumatoid arthritis: a ten-year, longitudinal observational study in 238 patients. Arthritis and Rheumatism. 2006;54:68–75
  79. Sokka T, Kautiainen H, Hannonen P, Pincus T. Changes in Health Assessment Questionnaire disability scores over five years in patients with rheumatoid arthritis compared with the general population. Arthritis and Rheumatism. 2006;54:3113–3118
  80. Wiles N, Barrett J, Barrett E, et al. Disability in patients with early inflammatory polyarthritis cannot be ‘tracked’ from year to year: an examination of the hypothesis underlying percentile reference charts. The Journal of Rheumatology. 1999;26:800–804
  81. Welsing PM, Fransen J, van Riel PL. Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis. Arthritis and Rheumatism. 2005;52:2616–2624
  82. Sharp JT. An overview of radiographic analysis of joint damage in rheumatoid arthritis and its use in metaanalysis. The Journal of Rheumatology. 2000;27:254–260
  83. Kaarela K, Kautiainen H. Continuous progression of radiological destruction in seropositive rheumatoid arthritis. The Journal of Rheumatology. 1997;24:1285–1287
  84. Wolfe F, Sharp JT. Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of radiographic progression. Arthritis and Rheumatism. 1998;41:1571–1582
  85. Plant MJ, Williams AL, O'Sullivan MM, et al. Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis. Arthritis and Rheumatism. 2000;43:1473–1477
  86. Bukhari M, Lunt M, Harrison BJ, et al. Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis and Rheumatism. 2002;46:906–912
  87. Paulus HE, Oh M, Sharp JT, et al. Correlation of single time-point damage scores with observed progression of radiographic damage during the first 6 years of rheumatoid arthritis. The Journal of Rheumatology. 2003;30:705–713
  88. Leak RS, Rayan GM, Arthur RE. Longitudinal radiographic analysis of rheumatoid arthritis in the hand and wrist. The Journal of Hand Surgery. 2003;28:427–434
  89. Lindqvist E, Jonsson K, Saxne T, Eberhardt K. Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis. Annals of the Rheumatic Diseases. 2003;62:611–616
  90. Verstappen SM, Jacobs JW, Bijlsma JW, et al. Five-year followup of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year. Arthritis and Rheumatism. 2003;48:1797–1807
  91. Wick MC, Anderwald C, Weiss RJ, et al. Radiological progression of joint damage in a longitudinal cohort of early DMARD-treated rheumatoid arthritis patients followed for 10 years. Scandinavian Journal of Rheumatology. 2004;33:162–166
  92. Sokka T, Kautiainen H, Hakkinen A, Hannonen P. Radiographic progression is getting milder in patients with early rheumatoid arthritis. Results of 3 cohorts over 5 years. The Journal of Rheumatology. 2004;31:1073–1082
  93. Lassere M, Houssein D, Scott D, Edmonds J. Reference curves of radiographic damage in patients with rheumatoid arthritis: application of quantile regression and fractional polynomials. The Journal of Rheumatology. 1997;24:1288–1294
  94. Graudal NA, Jurik AG, de Carvalho A, Graudal HK. Radiographic progression in rheumatoid arthritis: a long-term prospective study of 109 patients. Arthritis and Rheumatism. 1998;41:1470–1480
  95. Paulus HE, Oh M, Sharp JT, et al. Western Consortium of Practicing Rheumatologists. Classifying structural joint damage in rheumatoid arthritis as progressive or nonprogressive using a composite definition of joint radiographic change: a preliminary proposal. Arthritis and Rheumatism. 2004;50:1083–1096
  96. Machold KP, Stamm TA, Nell VP, et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology 2007; 46: 342–349.
  97. Scott DL, Dawes PT, Fowler PD, Shadforth MF. Calculating radiological progression in rheumatoid arthritis. Clinical Rheumatology. 1986;5:445–449
  98. van Riel PLCM, Scott DL. EULAR handbook of clinical assessment in rheumatoid arthritis. Alphen Aan Den Rijn, The Netherlands: Van Zuiden Communications; 2000;
  99. Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis and Rheumatism. 1995;38:44–48
  100. Scott DL, Antoni C, Choy EH, Van Riel PC. Joint counts in routine practice. Rheumatology (Oxford). 2003;42:919–923
  101. Wolfe F, Pincus T. The level of inflammation in rheumatoid arthritis is determined early and remains stable over the longterm course of the illness. The Journal of Rheumatology. 2001;28:1817–1824
  102. del Rincon ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis and Rheumatism. 2001;44:2737–2745
  103. Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003;107:1303–1307
  104. Warrington KJ, Kent PD, Frye RL, et al. Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study. Arthritis Research & Therapy. 2005;7:R984–R991
  105. Watson DJ, Rhodes T, Guess HA. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. The Journal of Rheumatology. 2003;30:1196–1202
  106. Goodson NJ, Wiles NJ, Lunt M, et al. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis and Rheumatism. 2002;46:2010–2019
  107. Liang KP, Liang KV, Matteson EL, et al. Incidence of noncardiac vascular disease in rheumatoid arthritis and relationship to extraarticular disease manifestations. Arthritis and Rheumatism. 2006;54:642–648
  108. Giles JT, Fernandes V, Lima JA, Bathon JM. Myocardial dysfunction in rheumatoid arthritis: epidemiology and pathogenesis. Arthritis Research and Therapy. 2005;7:195–207
  109. Gabriel SE, Crowson CS, O'Fallon WM. Comorbidity in arthritis. The Journal of Rheumatology. 1999;26:2475–2479
  110. Nicola PJ, Maradit-Kremers H, Roger VL, et al. The risk of congestive heart failure in rheumatoid arthritis: A population-based study over 46 years. Arthritis and Rheumatism. 2005;52:412–420
  111. Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. The Journal of Rheumatology. 2003;30:36–40
  112. Anaya JM, Diethelm L, Ortiz LA, et al. Pulmonary involvement in rheumatoid arthritis. Seminars in Arthritis and Rheumatism. 1995;24:242–254
  113. Remy-Jardin M, Remy J, Cortet B, et al. Lung changes in rheumatoid arthritis: CT findings. Radiology. 1994;193:375–382
  114. Kim DS. Interstitial lung disease in rheumatoid arthritis: recent advances. Current Opinion in Pulmonary Medicine. 2006;12:346–353
  115. Tanaka N, Kim JS, Newell JD, et al. Rheumatoid arthritis-related lung diseases: CT findings. Radiology. 2004;232:81–91
  116. Turesson C, Jacobsson L, Bergstrom U. Extra-articular rheumatoid arthritis: prevalence and mortality. Rheumatology. 1999;38:668–674
  117. Turesson C, O'Fallon WM, Crowson CS, et al. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Annals of the Rheumatic Diseases. 2003;62:722–727
  118. Turesson C, McClelland RL, Christianson TJ, Matteson EL. Multiple extra-articular manifestations are associated with poor survival in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 2006;65:1533–1534
  119. van der Helm-van Mil AH, Kern M, Gregersen PK, Huizinga TW. Variation in radiologic joint destruction in rheumatoid arthritis differs between monozygotic and dizygotic twins and pairs of unrelated patients. Arthritis and Rheumatism. 2006;54:2028–2030
  120. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis and Rheumatism. 1987;30:1205–1213
  121. Zanelli E, Breedveld FC, de Vries RR. HLA class II association with rheumatoid arthritis: facts and interpretations. Human Immunology. 2000;61:1254–1261
  122. de Jongh BM, van Romunde LK, Valkenburg HA, et al. Epidemiological study of HLA and GM in rheumatoid arthritis and related symptoms in an open Dutch population. Annals of the Rheumatic Diseases. 1984;43:613–619
  123. Thomson W, Harrison B, Ollier B, et al. Quantifying the exact role of HLA-DRB1 alleles in susceptibility to inflammatory polyarthritis: results from a large, population-based study. Arthritis and Rheumatism. 1999;42:757–762
  124. Weyand CM, Xie C, Goronzy JJ. Homozygosity for the HLA-DRB1 allele selects for extraarticular manifestations in rheumatoid arthritis. The Journal of Clinical Investigation. 1992;89:2033–2039
  125. Weyand CM, Hicok KC, Conn DL, Goronzy JJ. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Annals of Internal Medicine. 1992;117:801–806
  126. Wordsworth P, Pile KD, Buckely JD, et al. HLA heterozygosity contributes to susceptibility to rheumatoid arthritis. American Journal of Human Genetics. 1992;51:585–591
  127. Hall FC, Weeks DE, Camilleri JP, et al. Influence of the HLA-DRB1 locus on susceptibility and severity in rheumatoid arthritis. QJM. 1996;89:821–829
  128. Gorman JD, Lum RF, Chen JJ, et al. Impact of shared epitope genotype and ethnicity on erosive disease: a meta-analysis of 3,240 rheumatoid arthritis patients. Arthritis and Rheumatism. 2004;50:400–412
  129. Gorman JD, vid-Vaudey E, Pai M, et al. Lack of association of the HLA-DRB1 shared epitope with rheumatoid nodules: an individual patient data meta-analysis of 3,272 Caucasian patients with rheumatoid arthritis. Arthritis and Rheumatism. 2004;50:753–762
  130. Gorman JD, vid-Vaudey E, Pai M, et al. Particular HLA-DRB1 shared epitope genotypes are strongly associated with rheumatoid vasculitis. Arthritis and Rheumatism. 2004;50:3476–3484
  131. Eberhardt K, Fex E. Clinical course and remission rate in patients with early rheumatoid arthritis: relationship to outcome after 5 years. British Journal of Rheumatology. 1998;37:1324–1329
  132. Kaltenhauser S, Wagner U, Schuster E, et al. Immunogenetic markers and seropositivity predict radiological progression in early rheumatoid arthritis independent of disease activity. The Journal of Rheumatology. 2001;28:735–744
  133. Drossaers-Bakker KW, Zwinderman AH, Vlieland TP, et al. Long-term outcome in rheumatoid arthritis: a simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup. Arthritis and Rheumatism. 2002;47:383–390
  134. van Gaalen FA, van AJ, Huizinga TW, et al. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis and Rheumatism. 2004;50:2113–2121
  135. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, et al. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Research & Therapy. 2005;7:R949–R958
  136. van der Helm-van Mil AH, Huizinga TW, Schreuder GM, et al. An independent role of protective HLA class II alleles in rheumatoid arthritis severity and susceptibility. Arthritis and Rheumatism. 2005;52:2637–2644
  137. Begovich AB, Carlton VE, Honigberg LA, et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. American Journal of Human Genetics. 2004;75:330–337
  138. Lee AT, Li W, Liew A, et al. The PTPN22 R620W polymorphism associates with RF positive rheumatoid arthritis in a dose-dependent manner but not with HLA-SE status. Genes and Immunity. 2005;6:129–133
  139. Steer S, Lad B, Grumley JA, et al. Association of R602W in a protein tyrosine phosphatase gene with a high risk of rheumatoid arthritis in a British population: evidence for an early onset/disease severity effect. Arthritis and Rheumatism. 2005;52:358–360
  140. Wesoly J, van der Helm-van Mil AH, Toes RE, et al. Association of the PTPN22 C1858T single-nucleotide polymorphism with rheumatoid arthritis phenotypes in an inception cohort. Arthritis and Rheumatism. 2005;52:2948–2950
  141. Janssens AC, Steyerberg EW, Jiang Y, et al. Value of the HLA-DRB1 Shared Epitope for Predicting Radiographic Damage in Rheumatoid Arthritis Depends on the Individual Patient Risk Profile. The Journal of Rheumatology. 2006;33:2383–2389
  142. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, et al. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis and Rheumatism. 2006;54:1117–1121
  143. Johansson M, Arlestig L, Hallmans G, Rantapaa-Dahlqvist S. PTPN22 polymorphism and anti-cyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease. Arthritis Research & Therapy. 2006;8:R19
  144. Lard LR, Boers M, Verhoeven A, et al. Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage. Arthritis and Rheumatism. 2002;46:899–905

PII: S1521-6942(07)00062-9

doi: 10.1016/j.berh.2007.05.006

Best Practice & Research Clinical Rheumatology
Volume 21, Issue 5 , Pages 943-967 , October 2007

Article Tools

* Image Usage & Resolution